Americas Association of Sarcoidosis and Other Granulomatous Disorders 2024 conference highlights

Kristen Mathias; Susana Dominguez-Peñuela; Anjali Wagle; Carlos Pardo; Michelle Sharp; Nisha Gilotra

doi:10.36141/svdld.v42i3.17197

Authors

Kristen R. Mathias 1Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
Susana Dominguez-Peñuela Division of Neuroimmunology, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore
Anjali A. Wagle Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
Carlos A. Pardo Division of Neuroimmunology, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore
Michelle Sharp Division of Pulmonary and Critical Care, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore , Maryland
Nisha A. Gilotra Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

Keywords:

: Sarcoidosis, Multidisciplinary Approach, Conference report, cardiomyopathy, precision medicine, granuloma, biomarkers, fibrosis, Health disparities

Abstract

The Americas Association of Sarcoidosis and Other Granulomatous Disorders (AASOG) 2024 conference, held in Baltimore, Maryland, leveraged a multidisciplinary approach to disseminating and addressing the latest updates, challenges and opportunities in multisystemic sarcoidosis. The conference, aptly titled “The Art of Working Together for Progress,” featured insights from diverse perspectives in sarcoidosis both nationally and internationally. This review summarizes the key takeaways from the six conference sessions: I. Sarcoidosis Multidisciplinary Care, II. Health Disparities in Sarcoidosis, III. The Search for Precision in Sarcoidosis, IV. Clinical Outcomes in Sarcoidosis, V. Clinical Trials in Sarcoidosis, and VI. Advanced Disease in Sarcoidosis.

References

1. Arger N, Sharp M, Bonham C, Patel D, Gupta R, James WE. Sarcoidosis faculty development: The pipeline is running dry. Chest. 2024;166(3):528-31. doi: 10.1016/j.chest.2024.03.039

2. Sharp M, Eakin MN, Drent M. Socioeconomic determinants and disparities in sarcoidosis. Curr Opin Pulm Med. 2020;26(5):568-73. doi: 10.1097/MCP.0000000000000704

3. Gwadera Ł, Białas AJ, Górski W, et al. Gender differences in health-related quality of life measured by the Sarcoidosis Health Questionnaire. Sci Rep. 2021;11(1):10242. doi: 10.1038/s41598-021-89383-1

4. Arkema EV, Eklund A, Grunewald J, Bruze G. Work ability before and after sarcoidosis diagnosis in Sweden. Respir Med. 2018;144(Suppl):S7-12. doi: 10.1016/j.rmed.2018.09.016

5. Lundkvist A, Kullberg S, Arkema EV, et al. Differences in disease presentation between men and women with sarcoidosis: A cohort study. Respir Med. 2022;191:106688. doi: 10.1016/j.rmed.2021.106688

6. Rossman MD, Thompson B, Frederick M, et al. HLA and environmental interactions in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25(2):125-32.

7. Li J, Yang J, Levin AM, et al. Efficient generalized least squares method for mixed population and family-based samples in genome-wide association studies. Genet Epidemiol. 2014;38(5):430-8. doi: 10.1002/gepi.21811

8. Rivera NV, Patasova K, Kullberg S, et al. A gene-environment interaction between smoking and gene polymorphisms provides a high risk of two subgroups of sarcoidosis. Sci Rep. 2019;9(1):18633. doi: 10.1038/s41598-019-54612-1

9. Yang IV, Konigsberg I, MacPhail K, et al. DNA methylation changes in lung immune cells are associated with granulomatous lung disease. Am J Respir Cell Mol Biol. 2019;60(1):96-105. doi: 10.1165/rcmb.2018-0177OC

10. Konigsberg IR, Maier LA, Yang IV. Epigenetics and sarcoidosis. Eur Respir Rev. 2021;30(160):210076. doi: 10.1183/16000617.0076-2021

11. Oswald-Richter KA, Beachboard DC, Zhan X, et al. Multiple mycobacterial antigens are targets of the adaptive immune response in pulmonary sarcoidosis. Respir Res. 2010;11(1):161. doi: 10.1186/1465-9921-11-161

12. Bagavant H, Cizio K, Araszkiewicz AM, et al. Systemic immune response to vimentin and granuloma formation in a model of pulmonary sarcoidosis. J Transl Autoimmun. 2022;5:100153. doi: 10.1016/j.jtauto.2022.100153

13. Culver DA, Barna BP, Raychaudhuri B, et al. Peroxisome proliferator-activated receptor gamma activity is deficient in alveolar macrophages in pulmonary sarcoidosis. Am J Respir Cell Mol Biol. 2004;30(1):1-5. doi: 10.1165/rcmb.2003-0304RC

14. Linke M, Pham HTT, Katholnig K, et al. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol. 2017;18(3):293-302. doi: 10.1038/ni.3655

15. Ochoa D, Karim M, Ghoussaini M, Hulcoop DG, McDonagh EM, Dunham I. Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. Nat Rev Drug Discov. 2022;21(8):551. doi: 10.1038/d41573-022-00120-3

16. Garman L, Pezant N, Dawkins BA, et al. Inclusivity in research matters: Variants in PVT1 specific to persons of African descent are associated with pulmonary fibrosis. Am J Respir Crit Care Med. 2024;209(1):106-9. doi: 10.1164/rccm.202210-1969LE

17. Dawkins BA, Garman L, Cejda N, et al. Novel HLA associations with outcomes of Mycobacterium tuberculosis exposure and sarcoidosis in individuals of African ancestry using nearest-neighbor feature selection. Genet Epidemiol. 2022;46(7):463-74. doi: 10.1002/gepi.22490

18. Lockstone HE, Sanderson S, Kulakova N, et al. Gene set analysis of lung samples provides insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis. Am J Respir Crit Care Med. 2010;181(12):1367-75. doi: 10.1164/rccm.200912-1855OC

19. Su R, Li MM, Bhakta NR, et al. Longitudinal analysis of sarcoidosis blood transcriptomic signatures and disease outcomes. Eur Respir J. 2014;44(4):985-93. doi: 10.1183/09031936.00039714

20. Koth LL, Solberg OD, Peng JC, Bhakta NR, Nguyen CP, Woodruff PG. Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. Am J Respir Crit Care Med. 2011;184(10):1153-63. doi: 10.1164/rccm.201106-1143OC

21. Morimoto R, Unno K, Fujita N, et al. Prospective analysis of immunosuppressive therapy in cardiac sarcoidosis with fluorodeoxyglucose myocardial accumulation: The PRESTIGE study. JACC Cardiovasc Imaging. 2024;17(1):45-58. doi: 10.1016/j.jcmg.2023.05.017

22. Birnie D, Beanlands RSB, Nery P, et al. Cardiac sarcoidosis multi-center randomized controlled trial (CHASM CS-RCT). Am Heart J. 2020;220:246-52. doi: 10.1016/j.ahj.2019.10.003

23. Kron J, Crawford T, Mihalick V, et al. Interleukin-1 blockade in cardiac sarcoidosis: Study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART). J Transl Med. 2021;19(1):460. doi: 10.1186/s12967-021-03130-8

24. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. Br Med J. 1961;2(5261):1165-72. doi: 10.1136/bmj.2.5261.1165

25. Obi ON, Alqalyoobi S, Maddipati V, Lower EE, Baughman RP. High-resolution CT scan fibrotic patterns in stage IV pulmonary sarcoidosis: Impact on pulmonary function and survival. Chest. 2024;165(4):892-907. doi: 10.1016/j.chest.2023.10.021

26. Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: Presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):119-27.

27. Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc. 2013;10(4):362-70. doi: 10.1513/AnnalsATS.201303-069FR

28. Reich JM. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: Influence of stage, ethnicity, and corticosteroid therapy. Chest. 2002;121(1):32-9. doi: 10.1378/chest.121.1.32

29. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718-27. doi: 10.1056/NEJMoa1908681

30. Stern BJ, Royal W 3rd, Gelfand JM, et al. Definition and consensus diagnostic criteria for neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018;75(12):1546-53. doi: 10.1001/jamaneurol.2018.2295

31. Henderson AD, Tian J, Carey AR. Neuro-ophthalmic manifestations of sarcoidosis. J Neuroophthalmol. 2021;41(4):e591-7. doi: 10.1097/WNO.0000000000001079